fbpx

Acacia Pharma Group plc – Issue of Equity on Exercise of Options/Vesting of Performance Share Awards

Cambridge, UK and Indianapolis, US – 16 September 2019: Acacia Pharma Group plc (the “Company”) (EURONEXT: ACPH), a hospital pharmaceutical company focused on the development and commercialisation of new nausea and vomiting treatments for surgical and cancer patients, announces that application has been made to Euronext Brussels for the admission of the 192,498 Ordinary Shares of £0.02 each (the “New Ordinary Shares”) to trading on Euronext Brussels (“Admission”) to satisfy the exercise of options granted under the Company’s Enterprise Management Incentive Share Option Plan, Unapproved Share option Plan and the vesting of awards under the Company’s Performance Share Plan.  The New Ordinary Shares will rank pari passu in all respects with the Company’s existing Ordinary Shares in issue.

Following issue of the New Ordinary Shares, the Company’s total issued share capital will consist of 53,634,915 Ordinary Shares with one voting right per share. The Company does not hold any Ordinary Shares in Treasury. Therefore, following the issue of the New Ordinary Shares, the total number of voting rights in the Company is 53,634,915.

Contacts

Acacia Pharma Group plc
Mile Bolinder, CEO
Christine Soden, CFO
+44 1223 919760
IR@acaciapharma.com

Citigate Dewe Rogerson (Financial PR)
Mark Swallow, Shabnam Bashir, David Dible
+44 20 7638 9571
acaciapharma@citigatedewerogerson.com

Nyheder

Professor vil udvikle radioaktivt præcisionsmissil mod hjernekræft
21. februar 2020
Ny test kan afsløre farlige modermærker
14. februar 2020
Brainy Days – rejs med ind i hjernen
10. februar 2020

Lundbeckfonden

Lundbeckfonden Ventures

Lundbeckfonden Emerge